Santalis Pharmaceuticals

Santalis Pharmaceuticals, Inc. is a wholly owned subsidiary of Quintis Limited. (ASX: QIN).

Santalis is developing scientifically and clinically-validated over-the-counter and prescription products that utilize pharmaceutical­grade Quintis Sandalwood Album oil. Sandalwood Album (East Indian Sandalwood Oil) has well documented safety and anti-infective, anti­proliferative and anti-inflammatory properties are well suited to a number of prevalent and under­served conditions. Santalis is currently studying Sandalwood Album-based drug candidates in several Phase 2 clinical trials in Australia and the US for the treatment of psoriasis, warts, atopic dermatitis (eczema) and molluscum contagiosum. In addition, EISO is being evaluated in a Phase 2 clinical trial for prevention of oral mucositis in head and neck cancer patients undergoing high dose radiation therapy.

Mount Romance

Mount Romance has over 20 years of sandalwood oil distillation experience and is today the world’s largest distiller of sandalwood.

It is a wholly-owned subsidiary of Quintis, acquired in 2008, and provides processing and distillation for Quintis. Based in Albany, Western Australia, Mount Romance pioneered the product and market development of Australian sandalwood (Santalum Spicatum). Since acquiring Mt Romance Quintis has invested heavily in environmental sustainability; today the uses renewable energy and an award-winning water recycling system in the distillation process, and supports an indigenous harvesting program that was tabled at the United Nations.